B2B Technology Reseller & Systems Integrator, Healthcare Imaging & AI Computing

$13.4M

Revenue

$1.2M

SDE

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a B2B enterprise technology reseller and systems integrator that sells and configures high-performance computing hardware for demanding, technical buyers. The product catalog spans diagnostic and professional medical displays, AI and machine learning workstations, servers, supercomputers, storage, GPUs, and data-center infrastructure. Rather than being a pure box mover, the business layers technical sales, configuration, global procurement, fulfillment, and lifecycle support onto its e-commerce platform, which is where the differentiation and margin live.

The company serves more than 8,000 customers worldwide, including Fortune 500 accounts, hospitals and health systems, radiology and teleradiology groups, imaging centers, medical OEMs, engineering and research firms, AI developers, and startups. Its established medical imaging expertise is the durable core, while the AI, ML, and GPU-computing lines are the growth engine riding directly on the current buildout of high-performance and data-center infrastructure. The company operates through authorized reseller, OEM, and distribution programs with global manufacturers, from a leased 15,000 square foot facility in the Southwest US.

At roughly $13.4M in revenue and $1.175M of EBITDA, this is an 8.8% margin distribution business, which is typical for value-added reseller economics: real dollars sit in the technical services and integration layer, not the hardware markup. Reported revenue CAGR of 27.1% into the TTM ending July 2026 is impressive, but a large chunk of that likely reflects the AI hardware supercycle, which is a tailwind and a risk in the same breath. The single shareholder is seeking a strategic or financial partner to fund inventory, purchasing, and integration capacity to chase larger enterprise deals.

Why we like it

The medical imaging and diagnostic display niche is genuinely durable: hospitals and radiology groups must buy FDA-relevant professional displays and imaging workstations regardless of the economic cycle, which anchors the base business in essential, replacement-driven demand. That established expertise is the moat that keeps this from being a generic Newegg-style reseller. It also gives the buyer a credible base to underwrite even if AI demand cools.
Value-added reseller economics beat pure distribution because the technical sales, configuration, and integration layer commands margin and stickiness that commodity hardware never would. With 8,000+ customers and authorized reseller, OEM, and distribution programs already in place, switching costs come from trust and technical fit, not price. That is a defensible position for a $13M operator.
The AI, ML, GPU, and data-center product lines are riding the single largest capex wave in enterprise computing, and this business already has the channel relationships and fulfillment infrastructure to capture it. A reported 27.1% revenue CAGR into TTM July 2026 shows the platform is already converting that tailwind into growth. For a buyer, the demand curve is doing a lot of the work.
This is a lean, asset-light, e-commerce-driven operation running out of a single leased 15,000 square foot facility, which keeps fixed overhead low and makes the model scalable with working capital rather than headcount or bricks. An operator with capital to expand inventory and purchasing capacity can pursue larger Fortune 500 and institutional deals without rebuilding the platform.

How to improve it

Attack margin mix first: the business runs at roughly 8.8% EBITDA margin, so pushing more revenue through the integration, configuration, and lifecycle-support layer instead of pass-through hardware is the single highest-leverage lever. Package turnkey clinical workstations and enterprise builds as bundled solutions with service attach rather than quoting components. Even a few points of margin on $13M of revenue is meaningful EBITDA.
Build recurring revenue that does not exist today: layer in extended warranty, managed lifecycle support, hardware refresh subscriptions, and maintenance contracts on top of the installed base of 8,000+ customers. This converts one-time hardware sales into predictable annuity streams and materially improves the exit multiple. Start with the healthcare accounts where uptime is mission-critical.
Concentrate sales effort on enterprise and Fortune 500 land-and-expand rather than transactional volume, since the listing itself flags larger institutional deals as the opportunity. Assign named technical account managers to the top 50 accounts and build a structured expansion motion. Larger, stickier accounts smooth out the revenue lumpiness inherent in project-based hardware sales.
Deepen and formalize manufacturer relationships to secure better pricing tiers, priority allocation, and co-marketing dollars, which is especially valuable in constrained GPU and AI hardware supply. Higher authorization tiers directly translate into better buy prices and protected margin. This is a relationship lever that a well-capitalized owner can pull immediately.
Invest in inventory and working capital discipline as the growth engine, since this model scales on purchasing capacity, not payroll. Tighten forecasting so you carry the right AI and imaging inventory to win larger orders without stranding cash in slow-moving components. Working capital management will make or break the return here.
Expand into adjacent verticals and international markets already flagged by the seller, leveraging the existing platform, technical bench, and fulfillment capability. Engineering, research, and technology customers overlap heavily with the current base, so cross-selling costs little to activate. Be deliberate about regulatory and channel restrictions before entering new territories.

Diligence notes

Scrutinize the revenue quality and durability of the 27.1% CAGR: determine how much of the growth is a one-time AI hardware buying surge versus a repeatable base. Ask for revenue by product line and by year, and stress-test what happens to EBITDA if GPU and AI demand normalizes. This is the central underwriting question for the deal.
Analyze customer and supplier concentration carefully, since 8,000 customers can still mask a top-10 that drives most of the profit, and authorized reseller programs can be revoked or re-tiered by manufacturers. Request revenue concentration by customer and by manufacturer, plus copies of the key distribution agreements. Loss of a single OEM authorization could impair the business overnight.
Verify margin structure and working capital cycle in detail: 8.8% EBITDA margin on a distribution model leaves little room for error, so confirm gross margins by category, inventory turns, days sales outstanding, and any drop-ship versus stocked-inventory mix. Understand how much cash is tied up in inventory to support current sales. This determines the true capital intensity of the business.
Confirm the exact ask, deal structure, and seller transition, none of which are disclosed. The single shareholder is seeking a strategic or financial partner, which may mean a partial sale rather than a clean exit, so clarify whether they intend to stay, roll equity, or leave. Also nail down the lease terms on the Southwest US facility.
Validate any regulatory exposure tied to the medical imaging and diagnostic display lines, including FDA classification of products sold and any compliance obligations that transfer with the business. Healthcare buyers have procurement and certification requirements that can gate revenue. Understand what licenses or authorizations are required to keep selling into that channel.

Source

Originally listed on BizBuySell. View original listing →